Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by Jmk2454on Aug 13, 2019 1:55pm
74 Views
Post# 30022871

RE:RE:RE:RE:RE:RE:RE:RE:Volume

RE:RE:RE:RE:RE:RE:RE:RE:Volume
Belgiumboy wrote:
JMark80 wrote: October sounds about right. On another topic, if phase 2 was pivotal (perhaps with market surveillance) would they even need a marketing partner? Not too difficult to sell a drug that doesn't have any competition. Besides, isn't that a reason why they are acquiring a CBD extraction company?


Jmk, these are things I've also been thinking about in the last weeks. Indeed, chances are they won't even need a partnerschip. In my opinion the FDA themselves want this to be approved as soon as possible because it's a safe remedy and the research outcomes are extremely well. In this case the share price would go to the stars and I think that's very possible!


I totally agree with you. Maybe the FDA is currently working with them to get the fast track and breakthrough therapy (I think those are the two) approval in place and then as soon as 2b is done in October they could start marketing. Could it happen that quickly?  We know when this goes it’s going to go fast. 

Isn’t this board great today?  Having real discussions without distractions?  Although I had put certain posters on ignore so maybe nobody is responding to them - I thought I read they were gone again though. 
Bullboard Posts